25 XP   0   0   10

MiMedx Group Inc
Buy, Hold or Sell?

Let's analyse Mimedx together

PenkeI guess you are interested in MiMedx Group Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of MiMedx Group Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about MiMedx Group Inc

I send you an email if I find something interesting about MiMedx Group Inc.

Quick analysis of Mimedx (30 sec.)










What can you expect buying and holding a share of Mimedx? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
15.0%

What is your share worth?

Current worth
$0.96
Expected worth in 1 year
$2.05
How sure are you?
57.5%

+ What do you gain per year?

Total Gains per Share
$1.09
Return On Investment
14.3%

For what price can you sell your share?

Current Price per Share
$7.61
Expected price per share
$7.57 - $9.27
How sure are you?
50%

1. Valuation of Mimedx (5 min.)




Live pricePrice per Share (EOD)

$7.61

Intrinsic Value Per Share

$0.86 - $8.86

Total Value Per Share

$1.83 - $9.82

2. Growth of Mimedx (5 min.)




Is Mimedx growing?

Current yearPrevious yearGrowGrow %
How rich?$142.7m$31.6m-$3.2m-11.5%

How much money is Mimedx making?

Current yearPrevious yearGrowGrow %
Making money$16.4m-$7.5m$23.9m146.0%
Net Profit Margin18.7%-11.8%--

How much money comes from the company's main activities?

3. Financial Health of Mimedx (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#320 / 1031

Most Revenue
#90 / 1031

Most Profit
#67 / 1031

Most Efficient
#86 / 1031

What can you expect buying and holding a share of Mimedx? (5 min.)

Welcome investor! Mimedx's management wants to use your money to grow the business. In return you get a share of Mimedx.

What can you expect buying and holding a share of Mimedx?

First you should know what it really means to hold a share of Mimedx. And how you can make/lose money.

Speculation

The Price per Share of Mimedx is $7.61. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Mimedx.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Mimedx, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.96. Based on the TTM, the Book Value Change Per Share is $0.27 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.03 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Mimedx.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.425.6%0.111.4%-0.06-0.8%-0.03-0.4%0.000.0%
Usd Book Value Change Per Share0.9512.5%0.273.6%-0.03-0.4%0.030.4%0.010.2%
Usd Dividend Per Share0.000.1%0.000.0%0.000.0%0.010.1%0.000.1%
Usd Total Gains Per Share0.9612.6%0.273.6%-0.03-0.4%0.040.5%0.020.2%
Usd Price Per Share8.77-6.52-3.46-5.96-7.41-
Price to Earnings Ratio5.18--108.48--20.85--41.71--41.36-
Price-to-Total Gains Ratio9.15-3,050.31-46.97-756.47-419.19-
Price to Book Ratio9.10-177.50--7.43-138.86-76.15-
Price-to-Total Gains Ratio9.15-3,050.31-46.97-756.47-419.19-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.61
Number of shares131
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.01
Usd Book Value Change Per Share0.270.03
Usd Total Gains Per Share0.270.04
Gains per Quarter (131 shares)35.704.92
Gains per Year (131 shares)142.8219.70
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1114213331610
2128527673330
32427419104950
42569562136670
53711705168290
638548482098110
7499699123115130
841138113426131150
951281127730148170
1051423142033164190

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%3.09.00.025.0%4.016.00.020.0%20.020.00.050.0%20.048.00.029.4%
Book Value Change Per Share4.00.00.0100.0%9.03.00.075.0%12.07.01.060.0%23.013.04.057.5%41.023.04.060.3%
Dividend per Share1.00.03.025.0%1.00.011.08.3%3.00.017.015.0%6.00.034.015.0%6.00.062.08.8%
Total Gains per Share4.00.00.0100.0%9.03.00.075.0%12.07.01.060.0%23.013.04.057.5%41.023.04.060.3%

Fundamentals of Mimedx

About MiMedx Group Inc

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was incorporated in 2011 and is headquartered in Marietta, Georgia.

Fundamental data was last updated by Penke on 2024-03-20 23:43:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is very efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is underpriced.

1.1. Profitability of MiMedx Group Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Mimedx earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Mimedx to the Biotechnology industry mean.
  • A Net Profit Margin of 72.2% means that $0.72 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of MiMedx Group Inc:

  • The MRQ is 72.2%. The company is making a huge profit. +2
  • The TTM is 18.7%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ72.2%TTM18.7%+53.4%
TTM18.7%YOY-11.8%+30.5%
TTM18.7%5Y-7.0%+25.7%
5Y-7.0%10Y0.8%-7.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ72.2%-171.8%+244.0%
TTM18.7%-205.8%+224.5%
YOY-11.8%-262.1%+250.3%
5Y-7.0%-455.6%+448.6%
10Y0.8%-589.0%+589.8%
1.1.2. Return on Assets

Shows how efficient Mimedx is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Mimedx to the Biotechnology industry mean.
  • 26.2% Return on Assets means that Mimedx generated $0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of MiMedx Group Inc:

  • The MRQ is 26.2%. Using its assets, the company is very efficient in making profit. +2
  • The TTM is 6.9%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ26.2%TTM6.9%+19.3%
TTM6.9%YOY-4.4%+11.3%
TTM6.9%5Y-3.8%+10.7%
5Y-3.8%10Y0.1%-3.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ26.2%-12.5%+38.7%
TTM6.9%-12.2%+19.1%
YOY-4.4%-11.2%+6.8%
5Y-3.8%-13.4%+9.6%
10Y0.1%-14.7%+14.8%
1.1.3. Return on Equity

Shows how efficient Mimedx is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Mimedx to the Biotechnology industry mean.
  • 43.9% Return on Equity means Mimedx generated $0.44 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of MiMedx Group Inc:

  • The MRQ is 43.9%. Using its investors money, the company is very efficient in making profit. +2
  • The TTM is 138.1%. Using its investors money, the company is very efficient in making profit. +2
Trends
Current periodCompared to+/- 
MRQ43.9%TTM138.1%-94.1%
TTM138.1%YOY-6.5%+144.6%
TTM138.1%5Y149.6%-11.5%
5Y149.6%10Y77.5%+72.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ43.9%-15.8%+59.7%
TTM138.1%-15.7%+153.8%
YOY-6.5%-13.9%+7.4%
5Y149.6%-18.3%+167.9%
10Y77.5%-19.2%+96.7%

1.2. Operating Efficiency of MiMedx Group Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Mimedx is operating .

  • Measures how much profit Mimedx makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Mimedx to the Biotechnology industry mean.
  • An Operating Margin of 27.0% means the company generated $0.27  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of MiMedx Group Inc:

  • The MRQ is 27.0%. The company is operating very efficient. +2
  • The TTM is 10.8%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ27.0%TTM10.8%+16.2%
TTM10.8%YOY-9.8%+20.6%
TTM10.8%5Y-6.0%+16.8%
5Y-6.0%10Y0.4%-6.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ27.0%-299.1%+326.1%
TTM10.8%-210.1%+220.9%
YOY-9.8%-279.7%+269.9%
5Y-6.0%-459.9%+453.9%
10Y0.4%-596.9%+597.3%
1.2.2. Operating Ratio

Measures how efficient Mimedx is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.73 means that the operating costs are $0.73 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of MiMedx Group Inc:

  • The MRQ is 0.730. The company is efficient in keeping operating costs low. +1
  • The TTM is 0.892. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.730TTM0.892-0.162
TTM0.892YOY1.098-0.206
TTM0.8925Y1.040-0.148
5Y1.04010Y0.975+0.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7302.861-2.131
TTM0.8923.193-2.301
YOY1.0983.615-2.517
5Y1.0405.560-4.520
10Y0.9757.396-6.421

1.3. Liquidity of MiMedx Group Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Mimedx is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.57 means the company has $3.57 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of MiMedx Group Inc:

  • The MRQ is 3.570. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.378. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.570TTM3.378+0.193
TTM3.378YOY3.322+0.055
TTM3.3785Y2.614+0.764
5Y2.61410Y2.860-0.246
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.5703.986-0.416
TTM3.3784.440-1.062
YOY3.3225.552-2.230
5Y2.6146.158-3.544
10Y2.8606.492-3.632
1.3.2. Quick Ratio

Measures if Mimedx is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Mimedx to the Biotechnology industry mean.
  • A Quick Ratio of 2.95 means the company can pay off $2.95 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of MiMedx Group Inc:

  • The MRQ is 2.953. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.793. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.953TTM2.793+0.160
TTM2.793YOY2.782+0.012
TTM2.7935Y2.151+0.642
5Y2.15110Y2.459-0.307
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.9533.638-0.685
TTM2.7934.168-1.375
YOY2.7825.515-2.733
5Y2.1516.012-3.861
10Y2.4596.209-3.750

1.4. Solvency of MiMedx Group Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Mimedx assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Mimedx to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.40 means that Mimedx assets are financed with 40.3% credit (debt) and the remaining percentage (100% - 40.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of MiMedx Group Inc:

  • The MRQ is 0.403. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.894. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.403TTM0.894-0.491
TTM0.894YOY0.816+0.078
TTM0.8945Y0.754+0.139
5Y0.75410Y0.518+0.236
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4030.335+0.068
TTM0.8940.330+0.564
YOY0.8160.267+0.549
5Y0.7540.367+0.387
10Y0.5180.378+0.140
1.4.2. Debt to Equity Ratio

Measures if Mimedx is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Mimedx to the Biotechnology industry mean.
  • A Debt to Equity ratio of 67.5% means that company has $0.67 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of MiMedx Group Inc:

  • The MRQ is 0.675. The company is very able to pay all its debts with equity. +2
  • The TTM is 35.449. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ0.675TTM35.449-34.774
TTM35.449YOY0.547+34.902
TTM35.4495Y122.816-87.367
5Y122.81610Y61.626+61.190
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6750.376+0.299
TTM35.4490.398+35.051
YOY0.5470.334+0.213
5Y122.8160.429+122.387
10Y61.6260.476+61.150

2. Market Valuation of MiMedx Group Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Mimedx generates.

  • Above 15 is considered overpriced but always compare Mimedx to the Biotechnology industry mean.
  • A PE ratio of 5.18 means the investor is paying $5.18 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of MiMedx Group Inc:

  • The EOD is 4.494. Based on the earnings, the company is cheap. +2
  • The MRQ is 5.179. Based on the earnings, the company is cheap. +2
  • The TTM is -108.484. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD4.494MRQ5.179-0.685
MRQ5.179TTM-108.484+113.663
TTM-108.484YOY-20.846-87.639
TTM-108.4845Y-41.707-66.777
5Y-41.70710Y-41.360-0.347
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.494-2.643+7.137
MRQ5.179-2.418+7.597
TTM-108.484-2.742-105.742
YOY-20.846-4.123-16.723
5Y-41.707-6.257-35.450
10Y-41.360-6.478-34.882
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of MiMedx Group Inc:

  • The EOD is 28.817. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 33.210. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 15.363. Based on how much money comes from the company's main activities, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD28.817MRQ33.210-4.393
MRQ33.210TTM15.363+17.847
TTM15.363YOY28.136-12.773
TTM15.3635Y-11.036+26.399
5Y-11.03610Y43.865-54.901
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD28.817-3.244+32.061
MRQ33.210-2.939+36.149
TTM15.363-3.478+18.841
YOY28.136-5.592+33.728
5Y-11.036-8.473-2.563
10Y43.865-8.881+52.746
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Mimedx is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 9.10 means the investor is paying $9.10 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of MiMedx Group Inc:

  • The EOD is 7.896. Based on the equity, the company is overpriced. -1
  • The MRQ is 9.099. Based on the equity, the company is overpriced. -1
  • The TTM is 177.497. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD7.896MRQ9.099-1.204
MRQ9.099TTM177.497-168.398
TTM177.497YOY-7.429+184.927
TTM177.4975Y138.858+38.639
5Y138.85810Y76.148+62.710
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.8962.124+5.772
MRQ9.0992.041+7.058
TTM177.4972.118+175.379
YOY-7.4292.915-10.344
5Y138.8583.682+135.176
10Y76.1484.114+72.034
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of MiMedx Group Inc.

3.1. Institutions holding MiMedx Group Inc

Institutions are holding 66.692% of the shares of MiMedx Group Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Essex Woodlands Health Ventures19.185961.191528195249281952490
2023-12-31BlackRock Inc6.48720.002195335185956246.664
2023-12-31Vanguard Group Inc4.46880.001365672541300992.0211
2023-12-31State Street Corporation2.78240.00174088962-40377-0.9778
2023-12-31Paradigm Capital Management, Inc.2.33431.56483430400-50000-1.4366
2023-12-31Geode Capital Management, LLC1.72710.002325381821098384.5232
2023-12-31Cannell Capital LLC1.68824.717624809692072079.113
2023-12-31Morgan Stanley - Brokerage Accounts1.08030.00121587593102600.6505
2023-12-31Richmond Brothers Inc0.955621.46931404352-76980-5.1967
2023-12-31Divisadero Street Capital Management, LP0.87932.560612921611112161617.8672
2023-12-31Renaissance Technologies Corp0.85180.017125178516870015.5759
2023-12-31Charles Schwab Investment Management Inc0.77180.00251134213577045.3603
2023-12-31Royal Bank of Canada0.73430.0022107909725373730.7426
2023-12-31Northern Trust Corp0.73260.0017107658658700.5482
2023-12-31Goldman Sachs Group Inc0.66040.0008970474557733135.1291
2023-12-31Prudential Financial Inc0.63820.0124937960192102.0909
2023-12-31Arrowstreet Capital Limited Partnership0.62780.008592259525403237.9967
2023-09-30Kanen Wealth Management LLC0.62775.03159225238761110.4934
2023-12-31Royce & Associates, LP0.58690.0699862494-5500-0.6336
2023-12-31Federated Hermes Inc0.54940.0176807373-35247-4.183
Total 48.3796.676571083740+31556931+44.4%

3.2. Funds holding MiMedx Group Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Vanguard Total Stock Mkt Idx Inv2.28810.0018336258200
2024-02-29iShares Russell 2000 ETF1.90770.03672803576-458-0.0163
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.17660.01381729173-1774-0.1025
2024-02-29SPDR® S&P Biotech ETF1.16210.1761707749319201.9047
2023-12-31Fidelity Small Cap Index0.78170.03961148846131261.1557
2024-02-01iShares Russell 2000 Value ETF0.74110.0726108903713780.1267
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.47420.0136696848140002.0502
2024-01-31Fidelity Extended Market Index0.44140.01464866061720.9606
2024-02-29Schwab US Small-Cap ETF™0.37550.027655188300
2023-12-31Royce Small-Cap Opportunity Invmt0.36640.3669538418-22782-4.0595
2024-02-29Paradigm Micro-Cap0.34022.521350000000
2023-12-31Timpani Small Cap Growth Equity0.32311.59494747994747990
2024-01-31Calamos Timpani Small Cap Growth I0.31011.3834455788-19011-4.004
2024-02-29Vanguard Russell 2000 ETF0.28530.0359419203327568.4762
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.28320.03641614400
2023-12-31Xtrackers S&P Global Infra Swap ETF 1C0.27971.637541097500
2024-02-29Vanguard Health Care ETF0.27270.015740069279682.0289
2023-12-31Federated Hermes MDT SCG Institutional0.26750.7376393046-47881-10.8592
2023-12-31Federated Hermes MDT Small Cap Growth IS0.26750.7402393046-47881-10.8592
2023-12-31Federated Hermes MDT SCC Institutional0.24930.271636642993682.6236
Total 12.59349.736718506894+451700+2.4%

3.3. Insider Transactions

Insiders are holding 3.9% of the shares of MiMedx Group Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-03-13William Frank Iv HulseSELL203817.95
2024-02-20Ricci S WhitlowSELL152718.01
2024-02-16Ricci S WhitlowSELL154938.07
2023-11-21Rice DougBUY50007.16
2023-05-15Robert Benjamin SteinSELL36076.15
2023-05-10Peter M CarlsonSELL59765.93
2023-05-10Robert Benjamin SteinSELL58695.93
2023-05-10William Frank Iv HulseSELL58705.93
2023-05-04Robert Benjamin SteinSELL517565.34
2023-05-02William Lawrence PhelanSELL52003.8
2023-04-25Peter M CarlsonSELL60943.74
2023-04-25Robert Benjamin SteinSELL59873.74
2023-04-25William Lawrence PhelanSELL16283.74
2023-04-11Peter M CarlsonSELL61003.31
2023-04-11Robert Benjamin SteinSELL59963.31
2023-04-11William Lawrence PhelanSELL16323.31

4. Summary

4.1. Key Performance Indicators

The key performance indicators of MiMedx Group Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.9550.272+252%-0.031+103%0.031+2951%0.012+8145%
Book Value Per Share--0.9640.191+404%0.215+348%0.285+238%0.477+102%
Current Ratio--3.5703.378+6%3.322+7%2.614+37%2.860+25%
Debt To Asset Ratio--0.4030.894-55%0.816-51%0.754-47%0.518-22%
Debt To Equity Ratio--0.67535.449-98%0.547+23%122.816-99%61.626-99%
Dividend Per Share--0.0040.001+300%-+100%0.006-37%0.004-9%
Eps--0.4230.105+303%-0.063+115%-0.032+108%0.003+13917%
Free Cash Flow Per Share--0.0660.042+58%-0.035+153%-0.020+131%0.011+525%
Free Cash Flow To Equity Per Share--0.0060.027-79%-0.036+737%0.019-70%0.010-46%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--8.858--------
Intrinsic Value_10Y_min--0.864--------
Intrinsic Value_1Y_max--0.165--------
Intrinsic Value_1Y_min--0.012--------
Intrinsic Value_3Y_max--1.046--------
Intrinsic Value_3Y_min--0.101--------
Intrinsic Value_5Y_max--2.591--------
Intrinsic Value_5Y_min--0.260--------
Market Cap1118350380.000-16%1298627212.830960617548.208+35%508107285.000+156%876249739.142+48%1089773381.071+19%
Net Profit Margin--0.7220.187+285%-0.118+116%-0.070+110%0.008+8460%
Operating Margin--0.2700.108+151%-0.098+136%-0.060+122%0.004+5917%
Operating Ratio--0.7300.892-18%1.098-34%1.040-30%0.975-25%
Pb Ratio7.896-15%9.099177.497-95%-7.429+182%138.858-93%76.148-88%
Pe Ratio4.494-15%5.179-108.484+2195%-20.846+503%-41.707+905%-41.360+899%
Price Per Share7.610-15%8.7706.520+35%3.458+154%5.959+47%7.414+18%
Price To Free Cash Flow Ratio28.817-15%33.21015.363+116%28.136+18%-11.036+133%43.865-24%
Price To Total Gains Ratio7.937-15%9.1473050.315-100%46.968-81%756.466-99%419.191-98%
Quick Ratio--2.9532.793+6%2.782+6%2.151+37%2.459+20%
Return On Assets--0.2620.069+281%-0.044+117%-0.038+114%0.001+21491%
Return On Equity--0.4391.381-68%-0.065+115%1.496-71%0.775-43%
Total Gains Per Share--0.9590.273+252%-0.031+103%0.038+2450%0.016+5912%
Usd Book Value--142717000.00028358750.000+403%31610750.000+351%42004150.000+240%70132302.850+103%
Usd Book Value Change Per Share--0.9550.272+252%-0.031+103%0.031+2951%0.012+8145%
Usd Book Value Per Share--0.9640.191+404%0.215+348%0.285+238%0.477+102%
Usd Dividend Per Share--0.0040.001+300%-+100%0.006-37%0.004-9%
Usd Eps--0.4230.105+303%-0.063+115%-0.032+108%0.003+13917%
Usd Free Cash Flow--9776000.0006155000.000+59%-5144250.000+153%-2988900.000+131%1554600.000+529%
Usd Free Cash Flow Per Share--0.0660.042+58%-0.035+153%-0.020+131%0.011+525%
Usd Free Cash Flow To Equity Per Share--0.0060.027-79%-0.036+737%0.019-70%0.010-46%
Usd Market Cap1118350380.000-16%1298627212.830960617548.208+35%508107285.000+156%876249739.142+48%1089773381.071+19%
Usd Price Per Share7.610-15%8.7706.520+35%3.458+154%5.959+47%7.414+18%
Usd Profit--62688000.00016416500.000+282%-7549500.000+112%-4254150.000+107%671525.000+9235%
Usd Revenue--86832000.00080369250.000+8%66960250.000+30%74414950.000+17%68800375.000+26%
Usd Total Gains Per Share--0.9590.273+252%-0.031+103%0.038+2450%0.016+5912%
 EOD+4 -4MRQTTM+28 -7YOY+29 -65Y+26 -910Y+27 -8

4.2. Fundamental Score

Let's check the fundamental score of MiMedx Group Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-154.494
Price to Book Ratio (EOD)Between0-17.896
Net Profit Margin (MRQ)Greater than00.722
Operating Margin (MRQ)Greater than00.270
Quick Ratio (MRQ)Greater than12.953
Current Ratio (MRQ)Greater than13.570
Debt to Asset Ratio (MRQ)Less than10.403
Debt to Equity Ratio (MRQ)Less than10.675
Return on Equity (MRQ)Greater than0.150.439
Return on Assets (MRQ)Greater than0.050.262
Total9/10 (90.0%)

4.3. Technical Score

Let's check the technical score of MiMedx Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.144
Ma 20Greater thanMa 508.022
Ma 50Greater thanMa 1008.058
Ma 100Greater thanMa 2007.913
OpenGreater thanClose7.640
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Total Other Income Expense Net -1,453-98-1,551-1,737-3,2883,069-2193,6993,480



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets239,047
Total Liabilities96,330
Total Stockholder Equity142,717
 As reported
Total Liabilities 96,330
Total Stockholder Equity+ 142,717
Total Assets = 239,047

Assets

Total Assets239,047
Total Current Assets164,261
Long-term Assets74,786
Total Current Assets
Cash And Cash Equivalents 82,000
Net Receivables 53,871
Inventory 21,021
Other Current Assets 1,745
Total Current Assets  (as reported)164,261
Total Current Assets  (calculated)158,637
+/- 5,624
Long-term Assets
Property Plant Equipment 9,106
Goodwill 19,441
Intangible Assets 5,257
Long-term Assets Other 205
Long-term Assets  (as reported)74,786
Long-term Assets  (calculated)34,009
+/- 40,777

Liabilities & Shareholders' Equity

Total Current Liabilities46,008
Long-term Liabilities50,322
Total Stockholder Equity142,717
Total Current Liabilities
Short-term Debt 1,548
Accounts payable 9,048
Other Current Liabilities 36,960
Total Current Liabilities  (as reported)46,008
Total Current Liabilities  (calculated)47,556
+/- 1,548
Long-term Liabilities
Long term Debt 48,099
Long-term Liabilities Other 2,223
Long-term Liabilities  (as reported)50,322
Long-term Liabilities  (calculated)50,322
+/-0
Total Stockholder Equity
Common Stock146
Accumulated Other Comprehensive Income 133,532
Other Stockholders Equity -96,330
Total Stockholder Equity (as reported)142,717
Total Stockholder Equity (calculated)37,348
+/- 105,369
Other
Capital Stock146
Cash and Short Term Investments 82,000
Common Stock Shares Outstanding 148,076
Current Deferred Revenue-1,548
Liabilities and Stockholders Equity 239,047
Net Debt -33,901
Net Invested Capital 190,816
Net Working Capital 118,253
Property Plant and Equipment Gross 29,134
Short Long Term Debt Total 48,099



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-31
> Total Assets 
5
15
1
0
15,032,048
12,150
10,411
8,634
7,617
9,121
7,345
9,700
8,337
9,486
6,847
7,352
23,421
24,282
23,552
27,096
26,860
27,472
33,535
35,183
37,852
40,283
45,296
84,694
87,349
86,025
97,317
109,259
106,105
113,837
125,927
135,913
177,220
177,055
181,665
193,263
188,491
199,865
178,707
121,255
0
0
0
122,844
107,442
170,310
179,267
122,844
122,844
107,442
213,324
202,032
190,813
187,147
180,523
187,929
174,443
168,667
172,798
171,430
168,159
176,378
189,022
239,047
239,047189,022176,378168,159171,430172,798168,667174,443187,929180,523187,147190,813202,032213,324107,442122,844122,844179,267170,310107,442122,844000121,255178,707199,865188,491193,263181,665177,055177,220135,913125,927113,837106,105109,25997,31786,02587,34984,69445,29640,28337,85235,18333,53527,47226,86027,09623,55224,28223,4217,3526,8479,4868,3379,7007,3459,1217,6178,63410,41112,15015,032,04801155
   > Total Current Assets 
5
15
1
0
6,938,862
3,943
2,406
873
118
1,670
186
2,800
1,983
3,326
929
1,706
2,343
3,623
3,003
6,882
7,048
7,855
16,140
18,089
20,689
21,528
25,846
65,389
67,904
66,300
77,264
85,677
82,286
91,806
102,745
96,310
95,240
101,841
106,290
126,538
121,898
132,546
114,110
48,747
0
0
0
74,000
57,187
122,500
134,022
74,049
74,000
57,187
171,474
160,617
149,964
147,691
141,902
148,523
135,907
131,009
136,040
134,198
131,702
141,223
154,502
164,261
164,261154,502141,223131,702134,198136,040131,009135,907148,523141,902147,691149,964160,617171,47457,18774,00074,049134,022122,50057,18774,00000048,747114,110132,546121,898126,538106,290101,84195,24096,310102,74591,80682,28685,67777,26466,30067,90465,38925,84621,52820,68918,08916,1407,8557,0486,8823,0033,6232,3431,7069293,3261,9832,8001861,6701188732,4063,9436,938,86201155
       Cash And Cash Equivalents 
2
15
1
0
6,749,609
3,875
2,347
865
35
1,621
6
2,700
1,628
2,728
428
1,341
1,021
1,614
637
4,112
3,021
2,655
7,621
6,754
5,725
4,194
6,062
44,078
43,020
39,245
47,253
46,582
38,696
38,601
41,073
28,486
15,117
23,803
18,338
34,391
30,924
47,533
36,522
27,476
0
0
0
45,100
28,381
96,929
94,122
45,118
45,100
28,381
109,595
95,812
84,746
85,007
90,607
87,083
75,676
72,502
73,217
65,950
61,221
68,652
81,164
82,000
82,00081,16468,65261,22165,95073,21772,50275,67687,08390,60785,00784,74695,812109,59528,38145,10045,11894,12296,92928,38145,10000027,47636,52247,53330,92434,39118,33823,80315,11728,48641,07338,60138,69646,58247,25339,24543,02044,0786,0624,1945,7256,7547,6212,6553,0214,1126371,6141,0211,3414282,7281,6282,70061,621358652,3473,8756,749,60901152
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,750
6,000
7,250
6,500
3,000
2,500
0
0
0
0
0
0
0
0
0
0
-43,904
0
0
0
-43,904
-43,904
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000-43,904-43,904000-43,90400000000002,5003,0006,5007,2506,0005,7500000000000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
116
381
259
162
503
1,213
1,502
1,892
2,854
3,946
6,170
7,654
9,822
11,762
13,707
16,093
18,967
20,500
23,304
26,672
31,001
39,448
46,778
53,755
53,882
54,861
63,427
67,151
66,846
60,738
59,581
656
0
0
0
51,000
466
534
22,232
454
51,000
466
43,895
45,468
45,411
47,381
37,161
41,096
38,354
38,470
41,586
43,788
44,694
48,963
49,005
53,871
53,87149,00548,96344,69443,78841,58638,47038,35441,09637,16147,38145,41145,46843,89546651,00045422,23253446651,00000065659,58160,73866,84667,15163,42754,86153,88253,75546,77839,44831,00126,67223,30420,50018,96716,09313,70711,7629,8227,6546,1703,9462,8541,8921,5021,213503162259381116000000000000
       Other Current Assets 
4
0
0
0
189,253
68
59
8
83
49
180
0
172
122
124
91
249
234
255
165
377
292
547
658
1,186
1,352
1,544
1,337
2,279
2,326
1,968
1,540
2,341
2,647
2,741
3,609
5,774
5,970
6,212
1,288
1,200
1,024
926
9,023
0
0
0
42,075
11,912
7,537
3,739
5,818
5,216
7,292
5,469
3,371
3,530
1,816
860
2,809
2,571
2,570
2,582
2,631
2,306
3,110
2,311
1,745
1,7452,3113,1102,3062,6312,5822,5702,5712,8098601,8163,5303,3715,4697,2925,2165,8183,7397,53711,91242,0750009,0239261,0241,2001,2886,2125,9705,7743,6092,7412,6472,3411,5401,9682,3262,2791,3371,5441,3521,186658547292377165255234249911241221720180498385968189,2530004
   > Long-term Assets 
0
0
0
0
8,093,186
8,207
8,005
7,760
7,499
7,451
7,159
6,900
6,353
6,160
5,918
5,646
21,078
20,659
20,549
20,215
19,812
19,616
17,395
17,094
17,163
18,755
19,451
19,305
19,444
19,725
20,053
23,582
23,819
22,031
23,182
39,603
81,980
75,214
75,375
66,725
66,593
67,319
64,597
72,508
0
0
0
19,211
50,255
47,810
45,244
48,795
48,844
50,255
41,850
41,415
40,849
39,456
38,621
39,406
38,536
37,658
36,758
37,232
36,457
35,155
34,520
74,786
74,78634,52035,15536,45737,23236,75837,65838,53639,40638,62139,45640,84941,41541,85050,25548,84448,79545,24447,81050,25519,21100072,50864,59767,31966,59366,72575,37575,21481,98039,60323,18222,03123,81923,58220,05319,72519,44419,30519,45118,75517,16317,09417,39519,61619,81220,21520,54920,65921,0785,6465,9186,1606,3536,9007,1597,4517,4997,7608,0058,2078,093,1860000
       Property Plant Equipment 
0
0
0
0
1,452,436
1,583
1,548
1,470
1,376
1,268
1,159
1,000
954
947
861
757
826
741
917
869
806
949
1,000
1,072
1,154
2,991
3,762
4,086
4,289
4,680
5,052
5,447
6,440
7,184
8,376
9,475
12,123
13,049
13,757
13,786
13,763
14,419
13,264
14,091
0
0
0
17,424
16,377
14,672
16,810
17,424
14,991
20,452
14,286
15,060
14,611
13,417
12,755
13,861
13,123
12,377
11,640
11,256
10,628
10,003
9,535
9,106
9,1069,53510,00310,62811,25611,64012,37713,12313,86112,75513,41714,61115,06014,28620,45214,99117,42416,81014,67216,37717,42400014,09113,26414,41913,76313,78613,75713,04912,1239,4758,3767,1846,4405,4475,0524,6804,2894,0863,7622,9911,1541,0721,0009498068699177418267578619479541,0001,1591,2681,3761,4701,5481,5831,452,4360000
       Goodwill 
0
0
0
0
857,597
858
858
858
858
858
858
900
858
858
858
858
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
4,040
30,730
26,951
26,951
20,203
20,203
20,203
19,894
19,976
0
0
0
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,976
19,441
19,441
19,441
19,44119,44119,44119,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97619,97600019,97619,89420,20320,20320,20326,95126,95130,7304,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,0404,040858858858858900858858858858858858857,5970000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,250
2,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000000000002,5003,2500000000000000000000000000000000
       Intangible Assets 
0
0
0
0
5,783,153
5,616
5,450
5,283
5,116
4,950
4,783
4,600
4,430
4,263
4,096
3,929
16,092
15,758
15,424
15,090
14,757
14,423
12,174
11,912
11,649
11,724
11,649
11,179
11,115
11,004
10,960
10,845
10,813
10,781
10,740
10,763
33,710
27,693
27,249
23,268
22,788
22,289
10,377
10,033
0
0
0
9,608
8,292
8,104
7,952
9,608
9,608
8,292
7,168
6,004
5,918
5,750
5,620
5,383
5,265
5,141
4,992
5,852
5,706
5,565
5,395
5,257
5,2575,3955,5655,7065,8524,9925,1415,2655,3835,6205,7505,9186,0047,1688,2929,6089,6087,9528,1048,2929,60800010,03310,37722,28922,78823,26827,24927,69333,71010,76310,74010,78110,81310,84510,96011,00411,11511,17911,64911,72411,64911,91212,17414,42314,75715,09015,42415,75816,0923,9294,0964,2634,4304,6004,7834,9505,1165,2835,4505,6165,783,1530000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20,252
19,918
19,632
19,345
19,006
18,668
16,395
0
16,009
15,764
15,688
15,219
15,156
15,045
15,001
18,135
17,379
14,847
14,806
30,128
69,857
62,165
61,618
9,468
9,839
10,408
21,062
0
0
0
0
0
0
0
507
443
473
1
420
375
344
313
270
186
172
164
150
148
147
0
0
0
0001471481501641721862703133443754201473443507000000021,06210,4089,8399,46861,61862,16569,85730,12814,80614,84717,37918,13515,00115,04515,15615,21915,68815,76416,009016,39518,66819,00619,34519,63219,91820,2520000000000000000
> Total Liabilities 
18
37
29
36
15,178,481
842
3,534
4,427
5,461
7,709
4,827
3,600
928
1,261
1,144
1,252
11,036
11,357
11,699
15,200
14,364
11,803
14,353
15,175
6,259
7,392
9,758
11,126
11,110
11,536
16,061
19,930
19,704
20,597
25,405
27,925
62,977
55,450
58,388
60,263
59,455
52,595
36,235
47,458
0
0
0
73,189
69,090
145,626
139,692
73,189
73,189
69,090
109,346
202,182
106,834
101,790
93,837
187,847
89,383
89,776
192,318
189,418
186,105
189,044
187,692
96,330
96,330187,692189,044186,105189,418192,31889,77689,383187,84793,837101,790106,834202,182109,34669,09073,18973,189139,692145,62669,09073,18900047,45836,23552,59559,45560,26358,38855,45062,97727,92525,40520,59719,70419,93016,06111,53611,11011,1269,7587,3926,25915,17514,35311,80314,36415,20011,69911,35711,0361,2521,1441,2619283,6004,8277,7095,4614,4273,53484215,178,48136293718
   > Total Current Liabilities 
8
27
19
26
948,478
842
1,532
1,191
1,699
1,107
1,911
600
928
1,261
1,144
1,252
2,698
5,564
6,828
7,917
6,796
8,240
10,548
5,071
5,971
6,141
8,331
9,608
9,594
9,913
14,449
18,404
18,460
19,461
24,352
26,777
28,842
38,538
41,578
50,732
49,600
51,511
35,159
45,810
0
0
0
71,500
64,347
78,103
73,367
71,547
71,500
64,347
57,297
59,162
55,411
50,571
41,746
42,357
36,591
37,138
45,858
43,557
40,870
44,460
43,627
46,008
46,00843,62744,46040,87043,55745,85837,13836,59142,35741,74650,57155,41159,16257,29764,34771,50071,54773,36778,10364,34771,50000045,81035,15951,51149,60050,73241,57838,53828,84226,77724,35219,46118,46018,40414,4499,9139,5949,6088,3316,1415,9715,07110,5488,2406,7967,9176,8285,5642,6981,2521,1441,2619286001,9111,1071,6991,1911,532842948,4782619278
       Short-term Debt 
0
15
15
18
0
0
0
0
0
0
369
0
0
0
0
403
205
46
1,079
1,296
1,779
2,042
1,174
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31
21
15
9
0
0
0
0
0
0
3,750
3,750
3,750
3,750
3,750
0
3,750
3,750
0
0
0
0
0
0
1,440
0
0
0
1,548
1,5480001,4400000003,7503,75003,7503,7503,7503,7503,750000000915213100000000000000001,1742,0421,7791,2961,0794620540300003690000001815150
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
31
21
15
9
0
0
0
0
0
0
3,750
3,750
3,750
3,750
3,750
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000003,7503,7503,7503,7503,7500000009152131000000000000000000000000000000000000000
       Accounts payable 
7
10
1
6
948,478
842
1,532
0
0
0
0
0
0
1,261
0
0
1,687
1,619
5,713
3,909
2,957
3,199
5,235
1,252
1,057
1,838
2,206
2,491
2,619
2,446
2,759
3,661
5,379
5,614
7,244
6,633
13,059
9,678
11,162
11,436
10,892
11,504
8,767
8,454
0
0
0
14,864
66,694
10,792
9,420
14,864
9,756
10,691
9,049
8,765
6,925
10,563
6,881
7,385
8,120
8,075
8,820
8,847
7,823
8,150
9,170
9,048
9,0489,1708,1507,8238,8478,8208,0758,1207,3856,88110,5636,9258,7659,04910,6919,75614,8649,42010,79266,69414,8640008,4548,76711,50410,89211,43611,1629,67813,0596,6337,2445,6145,3793,6612,7592,4462,6192,4912,2061,8381,0571,2525,2353,1992,9573,9095,7131,6191,687001,2610000001,532842948,47861107
       Other Current Liabilities 
1
1
1
3
0
0
0
1,191
1,699
1,107
1,542
0
928
1,261
1,144
848
2,493
3,893
21
6,621
5,018
6,198
9,374
3,819
4,914
4,303
6,126
7,117
6,975
7,467
11,690
14,743
13,081
13,847
17,108
20,144
15,783
28,860
30,416
39,296
38,708
40,007
26,392
37,356
0
0
0
1,817
2,396
1,534
1,683
56,683
28,915
53,656
48,248
50,397
48,486
40,008
34,865
34,972
28,471
29,063
37,038
34,710
33,047
36,310
34,457
36,960
36,96034,45736,31033,04734,71037,03829,06328,47134,97234,86540,00848,48650,39748,24853,65628,91556,6831,6831,5342,3961,81700037,35626,39240,00738,70839,29630,41628,86015,78320,14417,10813,84713,08114,74311,6907,4676,9757,1176,1264,3034,9143,8199,3746,1985,0186,621213,8932,4938481,1441,26192801,5421,1071,6991,1910003111
   > Long-term Liabilities 
10
10
10
10
948,478
842
2,002
3,236
3,761
6,602
2,915
3,000
3,000
0
0
403
8,338
5,793
4,872
7,282
7,567
3,564
3,805
10,105
288
1,251
1,426
1,518
1,516
1,623
1,612
1,526
1,244
1,136
1,053
1,148
34,135
16,912
16,810
9,531
9,855
1,084
1,076
1,648
0
0
0
1,642
0
67,523
66,325
1,642
1,871
4,743
52,049
143,020
51,423
51,219
52,091
145,490
52,792
52,638
146,460
145,861
145,235
144,584
144,065
50,322
50,322144,065144,584145,235145,861146,46052,63852,792145,49052,09151,21951,423143,02052,0494,7431,8711,64266,32567,52301,6420001,6481,0761,0849,8559,53116,81016,91234,1351,1481,0531,1361,2441,5261,6121,6231,5161,5181,4261,25128810,1053,8053,5647,5677,2824,8725,7938,338403003,0003,0002,9156,6023,7613,2362,002842948,47810101010
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,745
3,019
3,243
3,494
4,012
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
61,906
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000061,9060000000000000000000000000004,0123,4943,2433,0192,7450000000000000000000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
91,108
91,568
92,030
92,494
92,494
92,494
92,494
92,494
92,494
0
92,494
92,494
0
0
0092,49492,494092,49492,49492,49492,49492,49492,49492,03091,56891,108000000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,427
3,595
3,625
4,537
4,548
320
311
6,092
288
1,250
1,427
1,518
1,517
1,623
1,612
1,526
1,244
1,136
1,053
1,117
34,135
16,912
16,810
9,500
9,834
1,069
1,067
0
0
0
0
0
0
0
938
621
623
622
970
3,755
847
0
0
4,869
0
0
0
2,335
4,027
3,252
0
0
003,2524,0272,3350004,869008473,75597062262362193800000001,0671,0699,8349,50016,81016,91234,1351,1171,0531,1361,2441,5261,6121,6231,5171,5181,4271,2502886,0923113204,5484,5373,6253,5957,4270000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
487
0
0
0
354
309
264
0
0
0
0
0
0
0
0
0
0
0
1,700
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,7000000000000026430935400048700000000000000000000000000000000000
> Total Stockholder Equity
-13
-22
-28
-36
14,230,003
11,308
6,877
4,207
2,156
1,412
2,518
0
7,409
8,225
5,703
6,101
12,385
12,926
11,852
11,897
12,497
15,668
19,183
20,007
31,593
32,892
35,538
73,568
76,238
74,489
81,256
89,329
86,401
93,240
100,522
107,988
114,243
121,605
123,277
133,000
129,036
147,270
142,472
73,797
0
0
0
49,655
38,352
24,684
39,575
49,655
30,339
38,352
103,978
-150
83,979
85,357
86,686
82
85,060
78,891
-19,520
-17,988
-17,946
-12,666
1,330
142,717
142,7171,330-12,666-17,946-17,988-19,52078,89185,0608286,68685,35783,979-150103,97838,35230,33949,65539,57524,68438,35249,65500073,797142,472147,270129,036133,000123,277121,605114,243107,988100,52293,24086,40189,32981,25674,48976,23873,56835,53832,89231,59320,00719,18315,66812,49711,89711,85212,92612,3856,1015,7038,2257,40902,5181,4122,1564,2076,87711,30814,230,003-36-28-22-13
   Common Stock
23
23
23
23
36,864
37
37
37
37
37
42
0
59
62
62
64
71
74
74
74
78
81
87
88
96
96
98
104
106
106
108
108
109
109
109
109
109
110
110
110
111
112
112
113
0
0
0
113
113
113
113
113
113
113
113
113
113
113
113
113
114
114
114
114
115
116
116
146
146116116115114114114114113113113113113113113113113113113113113000113112112111110110110109109109109109108108106106104989696888781787474747164626259042373737373736,86423232323
   Retained Earnings 
-1,454
-1,463
-1,468
-1,476
0
-21,186
-26,196
-29,240
-32,112
-33,709
-38,196
-40,400
-43,550
-46,246
-49,101
-51,827
-55,175
-57,678
-59,444
-62,021
-63,115
-63,859
-68,078
-69,684
-71,304
-72,062
-72,369
-73,796
-74,718
-75,108
-71,408
-67,575
-63,488
-58,058
-51,507
-38,129
-36,933
-34,958
-31,637
-26,155
-21,828
-13,759
3,698
-46,581
0
0
0
-76,560
-89,833
-107,043
-94,664
-76,560
-76,560
-89,833
-134,844
-151,424
-159,806
-161,585
-163,924
-161,709
-172,198
-183,066
-19,520
-17,988
-196,889
-195,689
-187,155
-133,678
-133,678-187,155-195,689-196,889-17,988-19,520-183,066-172,198-161,709-163,924-161,585-159,806-151,424-134,844-89,833-76,560-76,560-94,664-107,043-89,833-76,560000-46,5813,698-13,759-21,828-26,155-31,637-34,958-36,933-38,129-51,507-58,058-63,488-67,575-71,408-75,108-74,718-73,796-72,369-72,062-71,304-69,684-68,078-63,859-63,115-62,021-59,444-57,678-55,175-51,827-49,101-46,246-43,550-40,400-38,196-33,709-32,112-29,240-26,196-21,1860-1,476-1,468-1,463-1,454
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70,555
71,247
73,869
75,559
79,471
87,199
89,628
102,826
104,882
107,834
147,284
150,875
154,079
157,894
162,433
158,401
156,401
156,074
163,133
151,659
156,457
159,940
161,261
153,735
161,883
163,446
0
0
0
0
164,744
166,296
136,298
143,647
147,231
149,765
151,625
158,318
158,610
156,733
158,720
162,003
165,695
165,490
169,352
171,865
0
178,829
182,907
0
0
00182,907178,8290171,865169,352165,490165,695162,003158,720156,733158,610158,318151,625149,765147,231143,647136,298166,296164,7440000163,446161,883153,735161,261159,940156,457151,659163,133156,074156,401158,401162,433157,894154,079150,875147,284107,834104,882102,82689,62887,19979,47175,55973,86971,24770,55500000000000000000
   Treasury Stock000000-3-840-4,017-4,000-4,385-5,091-7,449-10,717-13,451-12,578-10,806-9,521-4,684-38,224-38,6420000-24,784-966-2,982-2,216-5,136-4-592-17,125-4,154-5,212-8,621-5,637-5,337-4,588-25-25-25-25-25-25-25-25-25-25-25-25-250000000000000000
   Other Stockholders Equity 
1,418
1,418
1,418
1,418
14,193,139
32,456
33,234
33,409
34,231
35,084
40,672
0
50,900
54,409
54,742
57,864
69,088
72,230
73,022
75,644
77,434
81,446
89,374
91,903
105,201
107,357
110,509
149,559
153,450
152,390
155,757
160,296
153,680
155,189
156,320
151,008
156,967
163,153
162,177
167,550
160,204
171,483
149,616
132,232
0
0
0
0
0
0
0
126,102
0
147,584
147,601
151,161
151,642
154,335
158,003
161,678
164,650
169,349
-92,608
-114
86,334
182,907
188,369
-96,330
-96,330188,369182,90786,334-114-92,608169,349164,650161,678158,003154,335151,642151,161147,601147,5840126,1020000000132,232149,616171,483160,204167,550162,177163,153156,967151,008156,320155,189153,680160,296155,757152,390153,450149,559110,509107,357105,20191,90389,37481,44677,43475,64473,02272,23069,08857,86454,74254,40950,900040,67235,08434,23133,40933,23432,45614,193,1391,4181,4181,4181,418



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue321,477
Cost of Revenue-54,634
Gross Profit266,843266,843
 
Operating Income (+$)
Gross Profit266,843
Operating Expense-229,727
Operating Income37,11637,116
 
Operating Expense (+$)
Research Development12,665
Selling General Administrative206,724
Selling And Marketing Expenses0
Operating Expense229,727219,389
 
Net Interest Income (+$)
Interest Income0
Interest Expense-6,457
Other Finance Cost-143
Net Interest Income-6,314
 
Pretax Income (+$)
Operating Income37,116
Net Interest Income-6,314
Other Non-Operating Income Expenses0
Income Before Tax (EBT)30,63337,142
EBIT - interestExpense = 30,633
30,633
73,896
Interest Expense6,457
Earnings Before Interest and Taxes (EBIT)37,09037,090
Earnings Before Interest and Taxes (EBITDA)40,517
 
After tax Income (+$)
Income Before Tax30,633
Tax Provision-597
Net Income From Continuing Ops4,33730,036
Net Income67,439
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses284,361
Total Other Income/Expenses Net-266,314
 

Technical Analysis of Mimedx
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Mimedx. The general trend of Mimedx is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Mimedx's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of MiMedx Group Inc.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 7.71 < 9.0394 < 9.27.

The bearish price targets are: 7.61 > 7.61 > 7.57.

Tweet this
MiMedx Group Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of MiMedx Group Inc. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

MiMedx Group Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of MiMedx Group Inc. The current macd is -0.08611084.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Mimedx price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Mimedx. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Mimedx price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
MiMedx Group Inc Daily Moving Average Convergence/Divergence (MACD) ChartMiMedx Group Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of MiMedx Group Inc. The current adx is 21.07.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Mimedx shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
MiMedx Group Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of MiMedx Group Inc. The current sar is 8.4136.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
MiMedx Group Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of MiMedx Group Inc. The current rsi is 38.14. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending down: The RSI is trending down. -1
MiMedx Group Inc Daily Relative Strength Index (RSI) ChartMiMedx Group Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of MiMedx Group Inc. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Mimedx price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
MiMedx Group Inc Daily Stochastic Oscillator ChartMiMedx Group Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of MiMedx Group Inc. The current cci is -183.28023955.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
MiMedx Group Inc Daily Commodity Channel Index (CCI) ChartMiMedx Group Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of MiMedx Group Inc. The current cmo is -35.63851719.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
MiMedx Group Inc Daily Chande Momentum Oscillator (CMO) ChartMiMedx Group Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of MiMedx Group Inc. The current willr is -68.90756303.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Mimedx is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
MiMedx Group Inc Daily Williams %R ChartMiMedx Group Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of MiMedx Group Inc.

MiMedx Group Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of MiMedx Group Inc. The current atr is 0.29712223.

MiMedx Group Inc Daily Average True Range (ATR) ChartMiMedx Group Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of MiMedx Group Inc. The current obv is 12,007,489.

MiMedx Group Inc Daily On-Balance Volume (OBV) ChartMiMedx Group Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of MiMedx Group Inc. The current mfi is 41.67.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
MiMedx Group Inc Daily Money Flow Index (MFI) ChartMiMedx Group Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for MiMedx Group Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-03STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-11-16WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-05MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-06MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-01-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

MiMedx Group Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of MiMedx Group Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5038.144
Ma 20Greater thanMa 508.022
Ma 50Greater thanMa 1008.058
Ma 100Greater thanMa 2007.913
OpenGreater thanClose7.640
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Mimedx with someone you think should read this too:
  • Are you bullish or bearish on Mimedx? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Mimedx? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about MiMedx Group Inc

I send you an email if I find something interesting about MiMedx Group Inc.


Comments

How you think about this?

Leave a comment

Stay informed about MiMedx Group Inc.

Receive notifications about MiMedx Group Inc in your mailbox!